logo-loader
RNS
Corilis Digital Infrastructure Limited

Cordiant Digital Inf - Transaction in Own Shares

RNS Number : 7039C
Cordiant Digital Infrastructure Ltd
12 February 2024
 

 

CORDIANT DIGITAL INFRASTRUCTURE LIMITED

 

 

LEI: 213800T8RBBWZQ7FTF84

 

12 February 2024

 

 

 

Repurchase of Ordinary Shares

 

Cordiant Digital Infrastructure Limited (the "Company") announces that it purchased 769,230 ordinary shares of no par value in the capital of the Company ("Ordinary Shares") on 09 February 2024 at a price of 65.00 pence per Ordinary Share.  The repurchased Ordinary Shares will be held in treasury.

 

Following the repurchase, the total number of treasury shares held by the Company is 7,269,230 and the number of shares in issue less those shares held in treasury is 766,290,477. The figure of 766,290,477 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information, please visit www.cordiantdigitaltrust.com or contact:

 

Aztec Financial Services (Guernsey) Limited

Company Secretary and Administrator

Chris Copperwaite / Laura Dunning 

 

+44 (0) 1481 74 9700

Cordiant Capital, Inc.

Investment Manager

Stephen Foss, Managing Director

 

+44 (0) 20 7201 7546

Celicourt

Financial Communications Adviser

Philip Dennis / Felicity Winkles

 

+44 (0) 20 8434 2643

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSEKLFBZLLFBBD
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics, Helium One Global, Rockfire Resources, Cordiant...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) grew second-half sales by more than 12% after launching its grass pollen treatment Grassmuno in Germany, its largest market. Annual revenue rose 9% to £59.9 million, but the operating loss widened to £38.6 million, and shareholders will vote on...

6 days, 12 hours ago

2 min read